Skin Disorders News

Multiple factors influenced the complex nature of chronic pruritus and affected the quality of life in patients with the condition, according to results from nationwide telephone surveys.

Women who experience adverse life events during the second half of gestation are more likely to increase a child’s risk for atopic disorders, asthma and eczema, according to researchers.

The FDA approved omalizumab for the treatment of chronic idiopathic urticaria, a form of chronic hives, according to a press release. It is the first medication approved for the condition since H1-antihistamines.

The FDA approved omalizumab for the treatment of chronic idiopathic urticaria, a form of chronic hives, according to a press release. It is the first medication approved for the condition since H1-antihistamines.

Benzophenones have been named the American Contact Dermatitis Society’s Allergen of the Year for 2014 in an effort to raise awareness for allergy and photoallergy to ubiquitous agents, according to researchers.

Many agents prescribed for allergic disease in children are done so on an off-label or unlicensed basis, according to recent results.

Novartis has announced that omalizumab has been approved by the European Commission as an add-on therapy for chronic spontaneous urticaria in adults and adolescents with inadequate response to H1-antihistamine treatment.

PuraCap Pharmaceutical has announced its participation in a phase 2 trial to assess daily treatment of its topical ceramide-dominant complete lipid mixture to prevent eczema in infants at risk for allergic conditions.

SAN DIEGO — Patients with moderate-to-severe atopic dermatitis treated with dupilumab monotherapy displayed rapid improvement in disease activity and pruritus compared with those treated with placebo, according to late-breaking data presented at the 2014 American Academy of Allergy, Asthma & Immunology annual meeting.

SAN DIEGO — Rare variants in the IFNGR1 gene contributed to atopic dermatitis with eczema herpeticum susceptibility, according to late-breaking data presented at the 2014 American Academy of Allergy, Asthma and Immunology annual meeting.